Investors · Seed round open

Building the next class of immunotherapy.

IMYUN is advancing Immune-Tag Conjugates™ (ITCs™), a new class of recombinant protein therapy that redirects preexisting pathogen-primed T-cell memory onto the cells that drive disease.

01 Overview

Our lead program, ORION™, is in advanced preclinical development for HER2+ bladder cancer (TCC) and head-and-neck squamous cell carcinoma (HNSCC). Technology POC and initial in vivo proof of concept are complete. The platform extends across additional solid tumor markers and into autoimmune disease.

ORION™ is being validated through a HER2 proof-of-concept path, with bladder cancer (TCC) and head-and-neck squamous cell carcinoma (HNSCC) as leading clinical-entry options. The company’s long-term strategy is to apply ORION™ to higher-value oncology targets across multiple cancer types.

02 Why IMYUN

Why IMYUN.

A Large Unmet Need $200B global immuno-oncology market. Most solid tumors still escape and relapse. Checkpoint inhibitors, ADCs, and CAR-Ts cap at 25–50% response. 40–50% of tumors lose the target marker under treatment. $200B market
Compelling Initial Data In a HER2⁺ BCG-primed in vivo model: Significant reduction in tumor volume vs. controls (p<0.00076). 11× increase in active T-cells (CD3⁺CD44⁺) per 10⁵ cells. TME shift from 30.5% exhausted T-cells to 1.1%. Killing confirmed ex vivo by BCG-primed splenocytes (p<0.009). P < 0.00076
Differentiated Mechanism Unlike checkpoint inhibitors, ADCs, or CAR-Ts, ORION™ is designed to: Redirect preexisting pathogen-specific T-cell memory. Deliver multi-epitope coverage across MHC backgrounds. Outlast ADC resistance via epitope spreading. Manufacture cleanly as a recombinant protein. No cell therapy. No viral vectors. No cold chain. First-in-class
Validation Tag. Signal peptides have been clinically tested in humans as T-cell ultimate tags. Mechanism. Pathogen-derived T-cells selectively kill tagged tumor cells in vitro and in vivo. Scaffold. ADC formats with established clinical precedent for safety. In vivo readout. Successful POC in BCG pre-immunized and HER2+ mouse tumor model. Human-validated
Defensible IP Core patent now in the PCT stage and covers ORION™ composition of matter, including 16 cell-surface antigen targets and 11 pathogen-derived signal peptide tags. Freedom-to-operate is supported by 15 years of tag-development work. Filed
Clinical Infrastructure Ongoing discussions with Brown University's Legorreta Cancer Center, via Co-founder Dr. Wafik El-Deiry, discoverer of p21. Brown University
Expansion Path Breast, gastric, ovarian, once the wedge is proven. The platform extends to TROP-2, Nectin-4, EGFR, BCMA, and into autoimmune disease, where pharma is currently paying nine figures for CD19-directed assets. 16 targets · 11 tags
03 Current Status

Current Status.

In vivo POC
Complete
Initial data in hand
Patent filed
16 · 11
Targets and tags
GMP program
Scoped
CMO partnership secured
Preclinical development
US-leading cancer center
First-in-class in-vivo studies
04 Investment Opportunity

18 months to inflection.

We are currently raising capital to run the definitive five-arm ADC comparator study and lock ORION™ first-in-class position. 18 months to inflection.

We partner with long-term investors who understand platform science, clinical translation, and category creation.

For investment inquiries contact
Leon-Ariel Boston
Chief Executive Officer
leon@imyunpharma.com